Novartis's Zortress gets US nod for kidney transplant rejection
This article was originally published in Scrip
Executive Summary
Novartis's immunosuppressant Zortress (everolimus) has been approved in the US for the prevention of kidney transplant rejection in adult patients with low-to-moderate immunologic risk.